RE:RE:RE:Don't believe these newly created aliases that 'magically'LaserStock29 wrote: Macer wrote: TLT has solved the longstanding isues with PDT specificity by fine tuning the Ruthinium based compounds and enhanced them by understanding how they target tumor transferrin receptor binding sites. They have also improved the techinical side of things by making the compounds responsive at different light intensities which broadens the application of light to different tissue depths and densities.
If the phase one trial mirrors the preclinical work that they have done, this will get real interesting, real fast. I for one see no reason why the results would not be reproduceable in humans because of the models they have used in the preclinical studies really are not that different than the way they will treat humans in the trial.
TLT is trading very cheap right now and I don't think people really understand how quickly things can progress once patients are enrolled in this upcoming study. Tis the beauty of biotech I guess.
If you are new to TLT do yourself a favor and go back and read the new releases about the pre-clinical studies and then make a your own decision about buying in or not. Don't base your decisions on what you read on this board. ( I can summarize it in medical terms, TLT is gonna knock one out of the park, think Jose Bautista bat flip)
Macer
98% rat bladder cell kill Just read that pr and watch the AGM on the theralase website.
greater than 98%, Fluroscence to detect the micro-metatasis... the Hardware modifications worked on by Dr.Lidge that makes an elegant 3 ribbon 12 sensor unit. The software upgrade ,Full monte vs Monte Carlo.
From mid 2014 to now, being what is a minor ITA away, and what's supposed to be at the end of this month.. 3 weeks past a legit 60 calander days... it should be approved..
Human trials.. are right around the corner...... although I've said.. not hilariously that it would be something if they made us wait until mid march to end of Q1..... garbage really.
I hope Dr.Lidge's words were more of a reflective on the whole TLC-2000 process rather than the ITA.... but meh.
Lidge in that article wasn't referring to tlc2000 or tlc3000, he was referring to Vogl's laser. I don't know anything about Vogl's laser so I can't compare. It's really not worth confusing our delays to his. From what I see, they haven't gone through the motions, no HC application, TLT has gone through the motions... years and years of development, and we're almost through those regulatory hoops. I imagine Vogl can use just about any exhisting approved laser anyway, it's all moot and irrelvant to us imo. Whay keep referring to Lidge and Vogl's laser/that article?
ITA approval for TLC3000 just around the corner and worth the wait,,,, not only for the tld1433 clinicals but for the eventualy future commercialization of the tlc3000 hardware. The laser used by Vogl to destroy the cancerous cells is not approved for use by Health Canada.
“We expect it might be approved in one or two years,” said Vogl.
A spokesperson for Health Canada said it has not received an application for the device to be cleared for use in Canada.